J Pathol Transl Med.  2022 Jul;56(4):217-224. 10.4132/jptm.2022.03.15.

Clinically undetected plasmacytoid urothelial carcinoma of the urinary bladder with non-mass-forming metastases in multiple organs: an autopsy case

• Asano Y
• Miyai K
• Yoshimatsu S
• Sasaki M
• Ikewaki K
• Matsukuma S

• KMID: 2531614
• DOI: http://doi.org/10.4132/jptm.2022.03.15

Abstract

This case report outlines a clinically undetected urinary bladder plasmacytoid urothelial carcinoma (PUC) with multiple metastases detected at autopsy. An 89-year-old man presented with edema in the lower limbs. Pleural fluid cytology revealed discohesive carcinomatous cells, although imaging studies failed to identify the primary site of tumor. The patient died of respiratory failure. Autopsy disclosed a prostate tumor and diffusely thickened urinary bladder and rectum without distinct tumorous lesions. Histologically, the tumor consisted of acinar-type prostate adenocarcinoma with no signs of metastasis. Additionally, small, plasmacytoid tumor cells were observed in the urinary bladder/rectum as isolated or small clustering fashions. These metastasized to the lungs, intestine, generalized lymph nodes in a non-mass-forming manner. Combined with immunohistochemical studies, these tumor cells were diagnosed PUC derived from the urinary bladder. Both clinicians and pathologists should recognize PUC as an aggressive histological variant, which can represent a rapid systemic progression without mass-forming lesions.

Keyword

Urothelial carcinoma; Plasmacytoid variant; Urinary bladder; Autopsy; Cancer of unknown primary

Figure

• 

  Fig. 1 Premortem microscopic findings. (A) Transurethral resection specimen showing urothelial carcinoma in situ with a stromal microinvasion. (B) Discohesive carcinomatous cells with signet-ring or plasmacytoid features in the cell block from pleural fluid was noted. Gross examination at autopsy. (C) Anterior view of the gross description of the pelvic organs. (D) A prostate tumor protruding into the urethra is detected (arrowheads). Around this tumor, the rectal wall and posterior wall of the urinary bladder are diffusely thickened.

• 

  Fig. 2 Microscopic findings. (A, B) The thickened lesion in the urinary bladder wall, showing diffuse infiltration of discohesive, plasmacytoid tumor cells in a single file pattern and small nests in the edematous lamina propria (A) and muscularis propria (B). (C) The plasmacytoid tumor cells consisted of oval-to-round, eccentrically located nuclei and abundant densely eosinophilic and occasionally vacuolated/signet-ring-cell like cytoplasm. (D) Massive tumor extension into the thickened rectal wall, seminal vesicles, and periprostatic tissue (arrows) close to the prostate cancer (arrowheads) is observed. (E, F) Diffuse positive immunoreactivity for GATA binding protein 3 (E) and negative immunoreactivity for NK3 homeobox1 (F) in the plasmacytoid tumor cells (arrows, both E and F), and vice versa, in the prostate cancer cells (arrowheads, both E and F) is observed.

• 

  Fig. 3 (A) Retained immunoreactivity for E-cadherin and moderate-intensity immunoreactivity for human epidermal growth factor receptor 2 (HER2) were noted in cancer cells. (B) Fluorescence in situ hybridization for the copy number of HER2 gene showing no HER2 amplification in cancer cells. DAPI-counterstained interphase nuclei are observed; the red and green signals indicate the HER2 and CEP17 signals, respectively. (C) Metastatic small clusters or isolated cancer cells in the lungs. (D) Immunostaining for D2-40 highlighting lymphatic invasion of cancer cells. (E) Metastatic cancer cells in the sacral bone marrow.

Reference

References

1. Sahin AA, Myhre M, Ro JY, Sneige N, Dekmezian RH, Ayala AG. Plasmacytoid transitional cell carcinoma: report of a case with initial presentation mimicking multiple myeloma. Acta Cytol. 1991; 35:277–80.

2. Zukerberg LR, Harris NL, Young RH. Carcinomas of the urinary bladder simulating malignant lymphoma: a report of five cases. Am J Surg Pathol. 1991; 15:569–76.

3. Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol. 2008; 32:752–7.

4. Kim DK, Kim JW, Ro JY, et al. Plasmacytoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of clinicopathological features and survival outcomes. J Urol. 2020; 204:215–23.

5. Sood S, Paner GP. Plasmacytoid urothelial carcinoma: an unusual variant that warrants aggressive management and critical distinction on transurethral resections. Arch Pathol Lab Med. 2019; 143:1562–7.

6. Chung AD, Schieda N, Flood TA, et al. Plasmacytoid urothelial carcinoma (PUC): imaging features with histopathological correlation. Can Urol Assoc J. 2017; 11:E50–7.

7. Simon CT, Skala SL, Killen PD, et al. Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. Diagn Pathol. 2019; 14:113.

8. Kohada Y, Kaiho Y, Ito J, et al. Progressive plasmacytoid variant bladder cancer with retroperitoneal dissemination: an autopsy case report. IJU Case Rep. 2020; 3:166–9.

9. Ando T, Watanabe K, Takahashi K, Mizusawa T, Sakai T, Katagiri A. Duodenal and rectal obstructions due to urothelial cancer infiltration from recurrent renal pelvic cancer in the bladder wall: an autopsy case. Urol Case Rep. 2019; 27:100903.

10. Tanaka A, Ohori M, Hashimoto T, et al. A case of plasmacytoid urothelial carcinoma of the bladder: rapid progression after transurethral resection. Hinyokika Kiyo. 2012; 58:101–3.

11. Miyai K, Ito K, Matsukuma S, Tsuda H. Frequent EGFR expression/EGFR amplification and lack of activating mutation in testicular choriocarcinoma. Pathol Int. 2020; 70:262–9.

12. Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013; 189:1656–61.

13. Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009; 40:1023–8.

14. Monn MF, Kaimakliotis HZ, Pedrosa JA, et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol. 2015; 33:18.

15. Cockerill PA, Cheville JC, Boorjian SA, et al. Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control. Urology. 2017; 102:143–7.

16. Li Q, Assel M, Benfante NE, et al. The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy. Eur Urol Focus. 2019; 5:104–8.

17. Perrino CM, Eble J, Kao CS, et al. Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients. Hum Pathol. 2019; 90:27–36.

18. Sangoi AR, Chan E, Stohr BA, Kunju LP. Invasive plasmacytoid urothelial carcinoma: a comparative study of E-cadherin and P120 catenin. Hum Pathol. 2020; 102:54–9.

19. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010; 21:815–9.

20. Kamoun A, de Reynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020; 77:420–33.